Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 21.6
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Strong growth
Data is available to registered users only
Data is available to registered users only
About
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Data is available to registered users only
Buy
Sell